Given that DPP4 inhibitors have been used as clinical therapies for diabetes (such as sitagliptin, saxagliptin, and vildagliptin) (15), this study might shed light on the therapeutic potential of DPP4 inhibitors for preventing or attenuating SARS-CoV-2 infection in specific tumor patients. Here, DPP4 is linked to diabetes mellitus.